Add new benefits! New research has found that these common hypoglycemic drugs can delay ovarian aging
The ovaries are the organs of early aging in women, characterized by a gradual decline in the number of follicles and the quality of oocytes, which accelerates around the age of 37 and affects longevity and body health.
How to delay ovarian senescence has been the focus of research.
Previously, A team led by Professor Tohru Minamino from the Juntendo University Graduate School of Medicine in Tokyo, Japan, published a paper entitled “SGLT2 inhibition eliminates senescent cells and alleviates” in the journal Nature Aging pathological aging “article.
The study found that caraglipzin can enhance the clearance of senescent cells by inhibiting SGLT2, thereby improving age-related phenotypic changes and thereby extending lifespan.
With that, A team of researchers from the Second Affiliated Hospital of Chongqing Medical University published an article entitled “Empagliflozin rescues lifespan and liver senescence in naturally aged mice” in the journal GeroScience.
The study found that englaglizin extended the lifespan of naturally aged mice and delayed liver aging.
Little is known about whether caraglipzin can delay ovarian aging.
Recently, A team of researchers from the Oklahoma City Veterans Affairs Medical Center published a study in the journal GeroScience entitled “Canagliflozin treatment prevents follicular exhaustion and attenuates. hallmarks of ovarian aging in genetically heterogenous mice”.
The study found that caraglizin treatment delayed ovarian aging in mice, resulting in higher follicular reserve in mice, and significantly reduced fibrosis, pro-inflammatory features, T cell accumulation, and multinuclear giant cell accumulation.
The researchers first found that caraglizin treatment led to a significant increase in the number of primordial follicles in mice, almost twice as much as in age-matched control mice.
Surprisingly, the follicle reserve of 12-month-old mice treated with caglipzin was similar to that of 6-month-old control mice, with early follicles:
This is also reflected in the primary follicle ratio. Together, these results suggest that treatment with caraglipzin improves ovarian follicular reserve in female mice of reproductive age.
Subsequently, the researchers wanted to determine whether calaglizin mediated improvements in ovarian reserve associated with age-related changes in ovarian characteristics.
By evaluating ovarian fibrosis, polynuclear giant cell formation, and T cell accumulation, the researchers found that treatment with cagliprazin reduced age-related ovarian fibrosis by about 50 percent and significantly reduced age-related lipofuscin accumulation in the ovaries.
In addition, the study found that caglizin treatment reduced age-related increases in ovarian T cells (CD3), which known to accumulate in aging ovaries.
Finally, using transcriptome sequencing and proteomic analysis, the researchers found that caraglipzin treatment significantly improved mitochondrial function and upregulated a pathway in the ovary associated with reduced PI3K/Akt signaling.
All in all, the study is the first to show that treatment with caraglipzin reduces pathological features associated with reproductive aging.
Specifically, the 6 – to 12-month-old mice treated with caglipzin had higher follicular reserve than the age-matched control group, and significantly reduced fibrosis, pro-inflammatory features, T-cell accumulation, and polyclonal giant cell accumulation.
These results suggest that caraglipzin has the potential to treat ovarian aging in women.
References:
- https://link.springer.com/article/10.1007/s11357-024-01465-w
- https://www.nature.com/articles/s43587-024-00762-5
- https://www.nature.com/articles/s43587-024-00642-y
